Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 3rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 3rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

January 19th 2015

ASH Presents Second Round of Tests, Treatments to Question Under Choosing Wisely Initiative

Mary K. Caffrey

January 19th 2015

Care Plans to Reduce Healthcare Utilization in Sickle Cell Disease

Surabhi Dangi-Garimella, PhD

January 19th 2015

Poster Presentations Cover Therapeutic Options in CML

Surabhi Dangi-Garimella, PhD

January 19th 2015

Pharmacists Ease Cancer Patients' Financial Burdens

A new study on the effects of cancer patients' financial burdens suggests that pharmacists can play a role in easing or preventing some of their stress.

January 19th 2015

Healthcare Costs in Need of Solutions: Experts at ASH Agree

Surabhi Dangi-Garimella, PhD

January 19th 2015

Session on Survivorship Outlines Surveillance Strategies in Non-Hodgkin Lymphoma

Mary K. Caffrey

January 19th 2015

Ibrutinib Demonstrates Significant Responses for Patients With Hard-to-Treat CLL/SLL, Phase 2 Data Show

Mary K. Caffrey

January 19th 2015

Study Suggests Method of Reducing Blood Clots Without Risking Bleeding

Mary K. Caffrey

January 16th 2015

UCLA Study Unveils Mechanism of Melanoma Drug Resistance

Researchers have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumor shrinkage.

January 16th 2015

Study Indicates Improved Survival in CRC Despite Lower Surgery Rates

The research, published in JAMA Surgery, analyzed data collected from NCI's SEER database, between 1988 till 2010, on stage 4 CRC patients who had surgery or not for primary tumor resection. Survival data on these patients was then analyzed and associated with their surgical status.

January 16th 2015

Predictive Value of Diagnostic Tests

January 16th 2015

Development and Use of Diagnostic Testing

January 16th 2015

Predictive Value of Diagnostic Testing

January 16th 2015

Clinical Utility of Genomic Testing

January 16th 2015

Use of Molecular Tests That Assess Risk of Recurrence

January 15th 2015

Spanish Team Identifies Gene Variant Responsible for Susceptibility to Peripheral Neuropathy

The authors of the research say that this information could be especially valuable for the Spanish population: "Even though these variants are rare or not frequent in the population, their frequency is greater in Spain than in other countries."

January 15th 2015

Metabolic Syndrome A Significant Risk Factor in Endometrial Cancer, Study Finds

Overall, metabolic syndrome was associated with a 39 percent to 103 percent increased risk of endometrial cancer in women 65 and older, according to the study.

January 15th 2015

Patients With Metastatic Colorectal Cancer Having Less Surgery, Yet Survival Rates Improving

With the dawn of the modern era of new chemotherapeutic and biologic agents available for managing their disease, patients with metastatic colorectal cancer are undergoing less surgery for the removal of their primary tumors.

January 15th 2015

Can We Follow the European Model to Curb Drug Costs, Asks Dr Peter Bach

In an Ope-Ed in The New York Times , Peter Bach, MD, from the Memorial Sloan Kettering Cancer Center, questions the rising drug prices and contemplates solutions.

January 14th 2015

ASCO Staff Raising Healthcare Issues with Federal and State Legislators

Members of the ASCO Government Relations Committee are busy meeting Members of Congress as well as State Affiliates to address a number of healthcare issue early in the year.

January 14th 2015

Cancer Treatments the Next Big Area for Cost Saving Opportunities

Laura Joszt, MA

Involving the pharmacy benefits manager earlier in the decision-making process could lead to cost savings on cancer treatments, Express Scripts Chief Executive Officer George Paz said at the J.P. Morgan Healthcare Conference in San Francisco, California.

January 14th 2015

Diagnostic Testing Guidelines for Lung Cancer to Be Revised

In addition to recommendations on alternate techniques, the revised guideline, being jointly developed by CAP, IASLC, and AMP, will also include testing for emerging biomarkers in lung cancer.

January 14th 2015

Express Scripts Wants Early Discussions to Help Lower Treatment Costs

After their decision to include Abbvie's triple combination for hepatitis C on their formulary, over Gilead's more expensive regimens, Express Scripts indicated at the J. P. Morgan Healthcare Conference that they'll continue the stance of choosing treatments that are equally effective but save costs, especially in cancer.

January 13th 2015

"Choose Wisely" in Rectal Cancer a Retrospective Study Indicates

The retrospective analysis of 145 patients with stage 2-3 rectal cancer found that the "wait and watch" approach, instead of surgery, in patients treated with chemotherapy might work just as well when measuring survival as an outcome.

January 13th 2015

Pharma Giants to Collaborate on Immuno-oncology Regimens

Merck and Eli Lilly have entered an agreement to collaborate on clinical trials to evaluate the former's recently approved PD-1 inhibitor, Keytruda (pembrolizumab) in combination with Lilly's oncology agents in several clinical trials targeting multiple tumor types.

January 13th 2015

Study Highlights Need to Reduce Global Teen Exposure to Second-hand Smoke

The study evaluated data collected through a global collaboration between research institutes in the United States, India, and Africa. Study results pointed to a high rate of exposure of non-smoking teenagers to second-hand smoke, both at home and outside.

January 12th 2015

Cancer Survivors Identify Lingering Medical, Financial Troubles

Laura Joszt, MA

The number of cancer survivors may be on the rise, but they experience continuing issues that can impair their quality of life beyond 5 years of survival, according to a new study published in Cancer.

January 12th 2015

Pfizer Gains Access to 23andMe's Genetic Mine

23andMe is betting its growing troves of genetic data will prove essential to drug companies, medical researchers, and even health and wellness companies.

January 12th 2015

A New Target in Difficult-to-Treat Breast Cancer?

The pre-clinical study by researchers at the Wellcome Trust Sanger Institute in UK point to the gene BCL11A as a possible driver of this aggressive form of breast cancer.

January 12th 2015

Nivolumab Phase 3 Trial in NSCLC Stopped Early; Superior OS

Mid-trial evaluation by an independent Data Monitoring Committee found overall survival with Opdivo (nivolumab) in the Checkmate-017 trial was significantly better than the control arm. BMS now plans to submit results to the FDA for approval of the PD-1 inhibitor in lung cancer.

...

143 144 145 146 147 148 149 150 151

...

186 >